Sign up to save your podcasts
Or
Share Do What You Enjoy – Marc de Garidel
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Do What You Enjoy – Marc de Garidel
This episode is special and the first in a series of four. In partnership with ESCP Business School, I’ll be giving the mic to students, the leaders of tomorrow, to discuss with seasoned healthcare executives about their journeys and leadership beliefs. We welcomed in this first episode, Marc De Garidel Chief Executive Officer at Abivax. Marc shared his personal story and leadership beliefs with the students and several of his insightful learnings. In his closing advice, he encouraged aspiring leaders to pursue their passions, learn from mistakes, and not be overly concerned about others’ opinions.
"You can't have impact if you don't take risks at some point"
MEET OUR GUEST Marc De Garidel Chief Executive Officer at Abivax.
Marc De Garidel, is CEO of Abivax after being the CEO of CinCor Pharma, a biopharmaceutical company that develops therapies for patients with cardiovascular diseases and recently acquired by AstraZeneca.
Marc is a graduate of École Spéciale des Travaux Publics (a leading French civil engineering school), and holds a Master’s degree from Thunderbird School of Global Management and an Executive MBA from Harvard Business School.
Marc began his career with Eli Lilly, then in 2000, he was appointed General Manager of Amgen’s French affiliate and progressively oversaw an increasing number of countries before heading the Southern region of Amgen International, the group’s most important region in terms of sales. In 2010, Marc left Amgen to become the CEO of Ipsen where he helped transform the company by focusing on research and development and expanding Ipsen's international presence. Under his leadership, Ipsen's market value increased significantly. Prior to joining CinCor, Marc served as CEO of Corvidia Therapeutics, a private Boston-based biotechnology company that was acquired by Novo Nordisk in August 2020.
In addition to that, Marc has had extensive non-profit responsibility as VP of EPFIA (Europe Pharma Association) for three years as well as chairing the French pharma association G5 for six years. Marc is also a recipient of the French Legion of Honor.
View all episodes
By Naji Gehchan
5
1515 ratings
This episode is special and the first in a series of four. In partnership with ESCP Business School, I’ll be giving the mic to students, the leaders of tomorrow, to discuss with seasoned healthcare executives about their journeys and leadership beliefs. We welcomed in this first episode, Marc De Garidel Chief Executive Officer at Abivax. Marc shared his personal story and leadership beliefs with the students and several of his insightful learnings. In his closing advice, he encouraged aspiring leaders to pursue their passions, learn from mistakes, and not be overly concerned about others’ opinions.
"You can't have impact if you don't take risks at some point"
MEET OUR GUEST Marc De Garidel Chief Executive Officer at Abivax.
Marc De Garidel, is CEO of Abivax after being the CEO of CinCor Pharma, a biopharmaceutical company that develops therapies for patients with cardiovascular diseases and recently acquired by AstraZeneca.
Marc is a graduate of École Spéciale des Travaux Publics (a leading French civil engineering school), and holds a Master’s degree from Thunderbird School of Global Management and an Executive MBA from Harvard Business School.
Marc began his career with Eli Lilly, then in 2000, he was appointed General Manager of Amgen’s French affiliate and progressively oversaw an increasing number of countries before heading the Southern region of Amgen International, the group’s most important region in terms of sales. In 2010, Marc left Amgen to become the CEO of Ipsen where he helped transform the company by focusing on research and development and expanding Ipsen's international presence. Under his leadership, Ipsen's market value increased significantly. Prior to joining CinCor, Marc served as CEO of Corvidia Therapeutics, a private Boston-based biotechnology company that was acquired by Novo Nordisk in August 2020.
In addition to that, Marc has had extensive non-profit responsibility as VP of EPFIA (Europe Pharma Association) for three years as well as chairing the French pharma association G5 for six years. Marc is also a recipient of the French Legion of Honor.